Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy

Po-Hong Liu¹,⁴, Chien-Wei Su¹,⁴, Chia-Yang Hsu⁴,⁷, Cheng-Yuan Hsia²,⁴, Yun-Hsuan Lee¹,⁴, Yi-Hsiang Huang¹,⁵, Rheun-Chuan Lee³,⁴, Han-Chieh Lin¹,⁴, Teh-Ia Huo¹,⁴,⁶*¹

¹ Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ² Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ³ Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴ Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ⁵ Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ⁶ Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ⁷ Department of Internal Medicine, University of Nevada School of Medicine, Reno, Nevada, United States of America

* tihuo@vghtpe.gov.tw

Abstract

Background & Aims

Controversies exist on staging and management of solitary large (>5 cm) hepatocellular carcinoma (HCC). This study aims to evaluate the impact of tumor size on Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy.

Methods

BCLC stage A and B patients were included and re-classified as single tumor 2–5 cm or up to 3 tumors ≤3 cm (group A; n = 657), single tumor >5 cm (group SL; n = 224), and multiple tumors >3 cm (group B; n = 351). Alternatively, 240 and 229 patients with solitary large HCC regardless of tumor stage received surgical resection (SR) and transarterial chemoembolization (TACE), respectively. The propensity score analysis identified 156 pairs of patients from each treatment arm for survival comparison.

Results

The survival was significantly higher for group A but was comparable between group SL and group B patients. Of patients with solitary large HCC, the 1-, 3- and 5-year survival rates were 88% versus 74%, 76% versus 44%, and 63% versus 35% between SR and TACE group, respectively (p<0.001). When baseline demographics were adjusted in the propensity model, the respective 1-, 3- and 5-year survival rates were 87% versus 79%, 76% versus 46%, and 61% versus 36% (p<0.001). The Cox proportional hazards model identified TACE with a 2.765-fold increased risk of mortality compared with SR (95% confidence interval: 1.853–4.127, p<0.001).

Conclusions

Patients with solitary large HCC should be classified at least as intermediate stage HCC. SR provides significantly better survival than TACE for solitary large HCC regardless of tumor stage. Further amendment to the BCLC classification is mandatory.
Introduction

Liver cancer accounts for more than 700,000 deaths each year, and is a major cause of cancer-related deaths globally.[1] Screening for hepatocellular carcinoma (HCC) in high-risk individuals to detect tumors at a curable stage is recommended by the current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver (EASL) management guidelines.[2, 3] Despite increased detection rate of small HCC by the screening programs, large HCC at disease presentation still remains common. Up to 32% of HCC had a tumor diameter > 5 cm, and another 10–20% of tumors were larger than 10 cm at the time of diagnosis.[4, 5]

Solitary large (single tumor > 5 cm in diameter) HCC presents a unique challenge to clinicians. The optimal classification and management for patients with solitary large HCC is under heated and ongoing debate. Current HCC management guidelines recommend curative treatment including surgical resection (SR) and radiofrequency ablation (RFA) for early stage HCC, whereas transarterial chemoembolization (TACE) is offered to patients with intermediate stage tumor.[2, 3, 6] The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system and is endorsed by the AASLD and EASL guidelines.[2, 3] In the original BCLC classification, resectability, rather than tumor size, was emphasized as an indicator between early and intermediate stage HCC.[7] However, other reports advocate 5 cm as the cut-off point between early and intermediate stage HCC (Table 1). The lack of clarity and resultant incongruity in interpretation of HCC staging continued to date.[8, 9]

For patients with solitary large HCC, the role of RFA is limited due to smaller thermal ablation zone of 3–4 cm with conventional RFA devices.[10] SR has been advocated as a safe procedure with reasonable long-term prognosis.[11, 12] The efficacy of TACE in patients with large HCC has also been reported.[13] However, the comparative efficacy between SR and TACE in solitary large HCC remains to be determined. This study has two aims. First, by analyzing a large treated cohort of HCC patients with preserved liver function, we determined whether solitary large HCC is better fitted into early or intermediate stage HCC. Second, we investigated the survival of patients with solitary large HCC regardless of tumor stage undergoing SR or TACE as their primary anti-cancer therapy. A propensity score matching analysis was used to reduce potential bias and to compare the long-term outcomes between patients with solitary large HCC treated by SR or TACE.

Patients and Methods

Patients

A total of 3,117 patients with newly diagnosed HCC admitted to Taipei Veterans General Hospital were retrospectively reviewed. Patients with early or intermediate stage HCC as well as patients with solitary large (> 5 cm) HCC regardless of BCLC stages were enrolled. Comprehensive demographics, tumoral status and liver disease burden were documented when diagnosis was confirmed. The long-term survival of patients was recorded. The study complies with the Declaration of Helsinki and had been approved by the Institutional Review Board of Taipei Veterans General Hospital (IRB protocol number 2014-06-013AC).

Diagnosis and Treatments

The diagnosis of HCC was confirmed based on HCC management guidelines from EASL or AASLD.[2, 3] Performance status was determined when HCC diagnosis was made.[14] Total tumor volume (TTV) was calculated based on tumor diameter.[15] Patients were censored at time of liver transplantation if they received transplantation as salvage therapy.
To investigate the impact of tumor nodularity and size on treatment allocation and long-term prognosis in patients without portal vein tumor thrombosis (PVTT) or tumor-related symptoms and with adequate liver function reserve (fulfilling either BCLC stage A or stage B), we defined three groups of patients. Group A was defined as patients having solitary tumor ranging from 2 cm to 5 cm in size or no more than 3 tumors not exceeding 3 cm in diameter. Group B encompassed patients with multiple tumors beyond 3 cm. Finally, group SL were patients with single tumor larger than 5 cm in size. Group A and group B were patients who were unambiguously classified as BCLC stage A or stage B by all experts. Group SL was isolated in order to examine the survival of patients with solitary large HCC.

The eligibility criteria of SR and TACE were reported previously,[16, 17] In general, SR was considered in patients with no main portal trunk involvement.[18] TACE was directed to patients without obvious contraindications to TACE or to patients unwilling to undergo SR.[19] TACE was also performed under emergent condition for patients with acute tumor hemorrhage. Full written informed consent was obtained before each treatment procedure, and patient records/information was anonymized and de-identified prior to analysis for this retrospective study.

### Propensity score matching analysis

We employed a propensity score matching analysis to investigate the relation between treatment modalities and clinical outcomes in this observational, non-randomized study. The propensity score method reduced bias in patient selection and generated matched pairs of patients for comparison of the long-term outcomes between SR and TACE.[20, 21] Variables which

---

**Table 1. Comparison of definitions on early and intermediate hepatocellular carcinoma in current literatures.**

| Authors       | Year | Source | Early HCC                                  | Intermediate HCC                        | Remark                                      |
|---------------|------|--------|-------------------------------------------|-----------------------------------------|--------------------------------------------|
| Llovet et al.[7] | 1999 | Table  | Single, 3 tumors <3cm                     | Large/Multinodular                      | Original BCLC system                       |
| Bruix et al.[34] | 2001 | Text   | Single <5cm, 3 tumors <3cm                | Not qualify for curative options        | EASL conference                            |
| Bruix et al.[35] | 2002 | Text   | Single ≤5cm, 3 tumors ≤3cm                | Exceeding stage A                       |                                            |
| Llovet et al.[36] | 2003 | Text   | Single <5cm, 3 tumors <3cm                | Exceeding stage A                       |                                            |
| Bruix et al.[37] | 2005 | Text   | Single, 3 tumors ≤3cm                     | Large/Multinodular                      | AASLD guideline                            |
| Forner et al.[38] | 2010 | Text   | Single, 3 tumors <3cm                     | Single large HCC, Multinodular          | BCLC system update                         |
| Omata et al.[24] | 2010 | Figure | Single ≤5cm, 3 tumors ≤3cm                | Single>5cm, >3tumors                    | APASL guideline                            |
| Bruix et al.[2] | 2011 | Text   | Single, 3 tumors ≤3cm                     | Large/Multinodular                      | AASLD guideline                            |
| EASL-EORTC[3]   | 2012 | Text   | Single, 3 tumors <3cm                     | Multinodular                             | EASL-EORTC guideline                       |
| Bolondi et al.[39] | 2012 | Text&Figure | Single resectable tumor 3| tumors <3cm | Single unresectable tumor >5cm Multinodular >3cm | Proposal of B1-B4 subclassification |
| Verslype et al.[25] | 2012 | Figure | Single <5cm, 3 tumors <3cm                | Multinodular                             | ESMO-ESDO guideline                        |
| Bolondi et al.[26] | 2013 | Text   | Single <5cm, 3 tumors <3cm                | Multinodular                             | AISF statement                             |
| Méndez-Sánchez et al.[27] | 2014 | Text   | Single ≤5cm, 3 tumors ≤3cm                | Large/Multinodular                      | LAASL guideline                            |

Patients with single tumor ≤2cm and patients with portal vein tumor thrombosis, extrahepatic tumor spreading, suboptimal performance status and Child-Turcotte-Pugh classification C cirrhosis are not included in this table.

AASLD, American Association for the Study of Liver Diseases; AISF, Italian Association for the Study of the Liver; APASL, Asian Pacific Association for the Study of the Liver; BCLC, Barcelona Clinic Liver Cancer; EASL, European Association for the Study of the Liver; EORTC, European Organisation for Research and Treatment of Cancer; ESDO, European Society for Digestive Oncology; ESMO, European Society for Medical Oncology; HCC, hepatocellular carcinoma, LAASL, Latin American Association for the Study of the Liver.

doi:10.1371/journal.pone.0155588.t001
might affect the treatment selection process were comprehensively included in the propensity score model. Binary logistic regression was employed to determine a continuous propensity score from 0 to 1. A nearest-neighbor match without replacement in a one-to-one ratio was performed to select patients receiving SR and TACE into further investigations. A pre-defined caliper width (0.2 of the standard deviation of the logit of the propensity score) was selected for better performance in estimating treatment effects.[22]

**Statistical analysis**

The two-tailed Fisher exact test or the Chi-squared test was employed for categorical variables. The Kruskal-Wallis test or the Mann-Whitney U test was utilized to compare continuous variables between two or more patient groups. Survival analysis was performed by the Kaplan-Meier method. Univariate analysis was used to identify potential prognostic factors. Variables with \( p \) value less than 0.1 in the univariate analysis were introduced into the Cox proportional hazards model where the adjusted hazard ratios (HR) and 95% confidence intervals (CI) were determined. A final \( p \) value less than 0.05 was considered significant. The statistical analysis was performed with SPSS for Windows version 21 (IBM, NY, USA).

**Results**

**Characteristics and survival of patients with early and intermediate HCC**

A total of 1,232 (40%) newly diagnosed HCC patients met the criteria for either BCLC stage A or stage B. Among these patients, 709 (58%) patients were classified as group A, whereas 224 (18%) and 299 (24%) patients were categorized as group SL and group B, respectively (Table 2). There were significantly different distributions on etiologies of chronic hepatic diseases, serum biochemistries, \( \alpha \)-fetoprotein (AFP) level, coagulation function, and tumor burden among group A, group SL, and group B patients (\( p < 0.05 \)). The three groups received different anti-cancer treatments (\( p < 0.05 \)). Group A patients had significantly better long-term survival when compared with group SL or group B patients (\( p = 0.001 \) and \( p < 0.001 \), respectively; Fig 1). The long-term prognosis between group B and group SL were similar (\( p = 0.154 \)).

Among group A HCC, patients with single tumor 2–5 cm had similar long-term survival compared with patients with up to 3 tumors no larger than 3 cm (\( p = 0.166 \)). During a median follow-up duration of 33 months, 194 (27%), 76 (34%) and 123 (41%) of patients of group A, group SL, and group B, respectively, died. The estimated 1-, 3-, and 5-year survival rates in group A, group SL, and group B were 96% vs. 90% vs. 88%, 81% vs. 68% vs. 66%, and 68% vs. 54% vs. 49%, respectively.

**Patients with solitary large HCC regardless of BCLC stages**

A total of 803 (26%) newly diagnosed HCC patients with solitary tumor larger than 5 cm in size were identified during study period. Among them, 240 (30%) and 229 (29%) patients received SR and TACE, respectively, as the primary therapy. The propensity score matching analysis identified 156 matched pairs of patients from each treatment group to compare therapeutic efficacy and survival.

**Characteristics and survival of patients with solitary large HCC regardless of BCLC stages receiving SR or TACE**

Significantly diverse etiologies of hepatic diseases were found in patients with solitary large HCC undergoing SR or TACE (\( p < 0.05 \); Table 3). The TACE group was significantly older and had more severe liver cirrhosis (both \( p < 0.001 \)). Alternately, the SR group was associated with
fewer portal vein thrombosis, smaller TTV, lower TIS and CLIP score, and better performance status (all \( p < 0.05 \)). Solitary large HCC patients receiving SR had statistically significantly improved survival compared to patients undergoing TACE (\( p < 0.001 \); Fig 2). During the follow-up duration, 63 (26%) and 101 (44%) of patients who underwent SR and TACE died, respectively. The 1-, 3-, and 5-year survival rates in the SR and TACE group were 88% vs 74%, 76% vs 44% and 63% vs 35%, respectively (\( p < 0.001 \)).

### Characteristics and survival of patients with solitary large HCC regardless of BCLC stages receiving SR or TACE in the propensity model

Table 4 shows the characteristics of HCC patients between the SR or TACE group in the propensity model. The baseline demographics, including etiologies of underlying hepatic diseases, serum biochemistry, degree of cirrhosis, tumoral factors, CLIP score, and performance status, were similar between SR and TACE group in the propensity model. SR patients in the propensity model had better long-term survival compared with TACE patients (\( p < 0.001 \); Fig 3).
During the follow-up period, 45 (29%) and 69 (44%) patients in the SR and TACE group, respectively, died. The 1-, 3-, and 5-year survival rates of patients receiving SR and TACE were 87% vs. 79%, 76% vs. 46% and 61% vs. 36% ($p<0.001$). Compared with TACE patients, SR patients had significantly better prognosis even when patients with PVTT were excluded from the analysis ($p<0.001$). SR was associated with improved survival both when tumor size was $5.0–9.9$ cm ($p=0.017$) and when tumor size $\geq 10.0$ cm ($p<0.001$).

**Prognostic factors analysis for solitary large HCC**

The univariate survival analysis revealed the following predictors of mortality in patients with solitary large HCC: serum albumin $< 4$ g/dL, bilirubin $\geq 1$ mg/dL, α-fetoprotein (AFP) level $\geq 400$ ng/mL, performance status $\geq 1$, tumor size $> 10$ cm, presence of PVTT, and

---

**Fig 1. Comparison of survival between hepatocellular carcinoma (HCC) patients with single tumor ranging from 2–5cm or up to 3 tumors $\leq 3$ cm (group A), single tumor $> 5$ cm (group SL), and multiple tumors $> 3$ cm (group B). Group A patients had significantly better long-term survival than group SL and group B patients ($p = 0.001$ and $p<0.001$, respectively). The prognosis was similar between group SL and group B patients ($p = 0.154$).**

doi:10.1371/journal.pone.0155588.g001
TACE treatment (all \( p < 0.01 \), Table 5). In the adjusted Cox multivariate survival analysis, there were 5 independent predictors associated with adverse outcome: serum albumin < 4 g/dL (HR 1.621, 95% CI 1.175–2.236, \( p = 0.003 \)), AFP level \( \geq 400 \) ng/mL (HR 2.223, 95% CI 1.591–3.107, \( p < 0.001 \)), tumor size > 10 cm (HR 1.501, 95% CI 1.081–2.083, \( p = 0.015 \)), presence of PVTT (HR 1.919, 95% CI 1.385–2.658, \( p < 0.001 \)) and TACE (HR 2.922, 95% CI 2.090–4.086, \( p < 0.001 \)).

Univariate survival analysis for patients in the propensity score model showed the following predictors of poor prognosis: age < 65 years, serum albumin < 4 g/dL, bilirubin \( \geq 1 \) mg/dL, AFP level \( \geq 400 \) ng/mL, tumor size > 10 cm, presence of PVTT, and TACE treatment (all \( p < 0.1 \)). In the adjusted Cox multivariate survival analysis, we confirmed 4 independent factors linked with decreased survival: AFP level \( \geq 400 \) ng/mL (HR 2.163, 95% CI 1.441–3.247, \( p < 0.001 \)), tumor size > 10 cm (HR 1.585, 95% CI 1.066–2.356, \( p = 0.023 \)), PVTT (HR 1.901, 95% CI 1.271–2.843, \( p = 0.002 \)) and TACE treatment (HR 2.765, 95% CI 1.853–4.127, \( p < 0.001 \)).

**Discussion**

There are intense debates on the classification and management of patients with solitary large (> 5 cm) HCC. We evaluated a large cohort of patients with solitary large HCC to investigate the impact of tumor size on HCC stratification and treatment strategies. From prognostic
perspective, we demonstrate that patients with solitary large HCC with preserved hepatic function and without PVTT or tumor-related symptoms should more appropriately fit into intermediate stage. We also show that for patients with solitary large HCC regardless of liver reserve, status of portal vein invasion and performance status, SR was associated with a significantly better long-term prognosis compared with TACE. Moreover, the Cox multivariate

Fig 2. Comparison of survival between solitary large (> 5 cm) hepatocellular carcinoma (HCC) patients receiving surgical resection (SR) or transarterial chemoembolization (TACE). Solitary large HCC patients receiving SR had significantly better long-term survival than patients receiving TACE (p<0.001).

doi:10.1371/journal.pone.0155588.g002
analysis confirmed that TACE was independently linked with decreased survival. Our results provide solid evidence for cancer staging and treatment in patients with solitary large HCC.

Traditionally, the survival data of HCC patients are based on untreated patients. With the advances in cancer management, the only possible approach to define prognosis and staging is to review the outcomes after treatment. We demonstrated that there was no significant difference in long-term survival between patients with single HCC/C21/5 cm and patients with multiple HCCs larger than 3 cm. Therefore patients with solitary large HCC should be classified as intermediate stage to better represent their nature and prognosis of disease. This staging strategy is not uncommon in current clinical practice. In a large cohort from the HCC East-West study group reporting outcomes after SR, patients with solitary large HCC were classified as intermediate stage. Furthermore, several consensus guidelines from Asia-Pacific, Europe, Latin America, and Italy all limit early stage HCC to those with single tumor ≤ 5 cm and up to 3 tumors ≤ 3 cm.

The resectability has been emphasized by the BCLC group as the boundary between early and intermediate stage HCC in patients with solitary large tumor. The BCLC group stated that single tumor beyond 5 cm should still be considered for surgical resection; in addition, patients with resectable solitary large HCC should be classified as early stage HCC, and

Table 4. Baseline demographics in solitary large hepatocellular carcinoma patients receiving SR or TACE in the propensity model.

| Variables                  | SR (n = 156) | TACE (n = 156) | p value |
|----------------------------|-------------|---------------|---------|
| Age (years, mean ± SD)     | 64±13       | 66±15         | 0.350   |
| Male, n (%)                | 131 (84)    | 133 (85)      | 0.875   |
| Positive for HBsAg, n (%)  | 91 (58)     | 83 (53)       | 0.425   |
| Positive for anti-HCV, n (%)| 27 (17)     | 28 (18)       | 1.000   |
| Alcoholism, n (%)          | 20 (13)     | 24 (15)       | 0.626   |
| Serum biochemistry (mean ± SD) |            |               |         |
| Albumin (g/dL)             | 3.9±0.5     | 3.9±0.4       | 0.443   |
| Bilirubin (mg/dL)          | 0.9±0.7     | 0.9±0.5       | 0.072   |
| Creatinine (mg/dL)         | 1.1±0.6     | 1.1±0.8       | 0.879   |
| INR of PT                  | 1.0±0.1     | 1.0±0.1       | 0.785   |
| ALT (U/L)                  | 71±102      | 71±84         | 0.170   |
| Sodium (mmol/L)            | 139±3       | 139±4         | 0.633   |
| AFP (ng/mL, mean ± SD)     | 1617±62893  | 22097±88044   | 0.787   |
| Performance status 0/1/2-4 (%) | 59/32/9     | 63/22/15      | 0.079   |
| CTP class A/B (%)          | 89/11       | 92/8          | 0.436   |
| CTP score (mean ± SD)      | 5.4±0.7     | 5.4±0.8       | 0.923   |
| MELD score (mean ± SD)     | 8.5±2.7     | 8.7±2.4       | 0.305   |
| Number of tumor (s) 1/2/3 (%) | 100/0/0     | 100/0/0       | 1.000   |
| Total tumor volume (cm³, mean ± SD) | 609±755     | 693±930       | 0.365   |
| Intrahepatic/extrahepatic portal vein tumor thrombosis, n (%) | 34/5 (22/3) | 31/12 (20/8) | 0.213   |
| TIS 0/1/2/3/4/5 (%)        | 0/31/24/19/22/4/0 | 0/28/22/31/16/3/0 | 0.163   |
| CLIP 0/1/2/3/4/5 (%)       | 37/18/17/13/15/0/0 | 31/21/13/15/2/0/0 | 0.146   |

AFP, α-fetoprotein; ALT, alanine transaminase; CLIP, Cancer of the Liver Italian Program; CTP, Child-Turcotte-Pugh; HBsAg, hepatitis B surface antigen; HCV, hepatitis C; INR, international normalized ratio; MELD, model for end-stage liver disease; PT, prothrombin time; SD, standard deviation; SR, surgical resection; TACE, transarterial chemoembolization; TIS, Taipei Integrated Scoring System

doi:10.1371/journal.pone.0155588.t004
unresectable solitary large HCC would be considered intermediate stage HCC.\[3, 28, 29\] However, a recent study using regret-based decision curve analysis to assess physician preferences toward SR and TACE on intermediate stage HCC showed a significant separation among physicians' preferences.\[30\] Therefore, using resectability per se as the staging criterion may raise uncertainty and add difficulties in comparing results between different institutions. Notably,
the eligibility of patients to receive RFA, TACE or targeted therapy was not included in the staging criteria of early, intermediate and advanced stage HCC. Taken together, we propose that patients with single HCC larger than 5 cm with no tumor-related symptoms, no PVTT, and with preserved liver function should be classified as intermediate stage HCC regardless of the treatment they receive.

The management of solitary large HCC remains a major treatment challenge. According to the current BCLC scheme, TACE is the recommended treatment for patients with intermediate stage HCC. TACE has been shown safe and effective in treating larger HCC.[13] However, therapeutic modalities including RFA or TACE are still potentially limited by a lack of complete tumor eradication.[4] Significant progress has been achieved in patient selection, surgical techniques, and post-operative management of HCC in recent years, and SR was associated with improved outcomes in carefully selected solitary large HCC patients.[5] To further clarify the impact of treatment selection on long-term prognosis, we analyzed a large cohort with solitary large HCC irrespective of their performance status, hepatic functional reserve or PVTT.

### Table 5. Univariate and multivariate survival analysis in solitary large hepatocellular carcinoma patients undergoing SR or TACE.

|                        | Number | Univariate analysis | Multivariate analysis |
|------------------------|--------|---------------------|----------------------|
|                        |        | HR                  | CI                   | p        | HR                  | CI                   | p        |
| All patients with solitary large hepatocellular carcinoma (n = 469) |        |                     |                      |          |                     |                      |          |
| Age (<65/65 years)     | 235/234| 0.932               | 0.685–1.266          | 0.651    | 1.621               | 1.175–2.236          | 0.003    |
| Sex (male/female)      | 391/78 | 1.065               | 0.704–1.610          | 0.766    |                     |                      |          |
| Albumin (≥4.0/<4.0g/dL)| 206/263| 1.822               | 1.328–2.500          | <0.001   |                      |                      |          |
| Bilirubin (<1/1mg/dL)  | 320/149| 1.666               | 1.215–2.283          | 0.002    | 2.223               | 1.591–3.107          | <0.001   |
| INR of PT (<1/1)       | 172/297| 1.271               | 0.925–1.746          | 0.139    | 1.501               | 1.081–2.083          | 0.015    |
| Creatinine (<1/1mg/dL) | 236/233| 0.934               | 0.687–1.269          | 0.663    | 1.585               | 1.066–2.356          | 0.023    |
| Sodium (≥140/140 mmol/L)| 214/255| 1.269               | 0.932–1.729          | 0.130    | 2.118               | 1.448–3.099          | <0.001   |
|AFP (<400/400ng/mL)    | 298/171| 1.903               | 1.389–2.606          | <0.001   | 2.223               | 1.591–3.107          | <0.001   |
| Performance status (0/1) | 270/199| 1.596               | 1.163–2.191          | 0.004    | 2.191               | 1.385–2.658          | <0.001   |
| Tumor size (<10/10cm)  | 305/164| 1.790               | 1.306–2.453          | <0.001   | 2.922               | 2.090–4.086          | <0.001   |
| Portal vein tumor thrombosis (no/yes) | 341/128| 2.410               | 1.749–3.321          | <0.001   | 2.223               | 1.591–3.107          | <0.001   |
| Treatment (SR/TACE)    | 240/229| 2.639               | 1.917–3.633          | <0.001   | 2.922               | 2.090–4.086          | <0.001   |

Patients selected in the propensity model (n = 312)

|                        | Number | Univariate analysis | Multivariate analysis |
|------------------------|--------|---------------------|----------------------|
| Age (<65/65 years)     | 142/170| 0.653               | 0.451–0.947          | 0.024    |                     |                      |          |
| Sex (male/female)      | 264/48 | 0.959               | 0.564–1.632          | 0.877    | 2.223               | 1.591–3.107          | <0.001   |
| Albumin (≥4.0/<4.0g/dL)| 140/172| 1.517               | 1.044–2.204          | 0.029    | 1.501               | 1.081–2.083          | 0.015    |
| Bilirubin (<1/1mg/dL)  | 219/93 | 1.471               | 0.998–2.169          | 0.051    | 1.519               | 1.091–2.201          | <0.001   |
| INR of PT (<1/1)       | 121/191| 1.131               | 0.776–1.648          | 0.522    | 1.501               | 1.081–2.083          | 0.015    |
| Creatinine (<1/1mg/dL) | 150/162| 0.802               | 0.555–1.159          | 0.240    | 1.919               | 1.385–2.658          | <0.001   |
| Sodium (≥140/140 mmol/L)| 149/163| 1.251               | 0.863–1.813          | 0.238    | 1.919               | 1.385–2.658          | <0.001   |
|AFP (<400/400ng/mL)    | 200/112| 1.989               | 1.356–2.918          | <0.001   | 2.163               | 1.441–3.247          | <0.001   |
| Performance status (0/1) | 191/121| 1.237               | 0.837–1.836          | 0.229    | 1.919               | 1.385–2.658          | <0.001   |
| Tumor size (<10/10cm)  | 206/106| 1.785               | 1.223–2.604          | 0.003    | 1.585               | 1.066–2.356          | 0.023    |
| Portal vein tumor thrombosis (no/yes) | 230/82 | 2.168               | 1.467–3.203          | <0.001   | 1.901               | 1.271–2.843          | 0.002    |
| Treatment (SR/TACE)    | 156/156| 2.118               | 1.448–3.099          | <0.001   | 2.765               | 1.853–4.127          | <0.001   |

The forpart of the parentheses was set as the reference group in the univariate and multivariate analysis

AFP, α-fetoprotein; CI, confidence interval; HR, hazard ratio; INR, international normalized ratio; PT, prothrombin time; SR, surgical resection; TACE, transarterial chemoembolization

doi:10.1371/journal.pone.0155588.t005

The eligibility of patients to receive RFA, TACE or targeted therapy was not included in the staging criteria of early, intermediate and advanced stage HCC. Taken together, we propose that patients with single HCC larger than 5 cm with no tumor-related symptoms, no PVTT, and with preserved liver function should be classified as intermediate stage HCC regardless of the treatment they receive.

The management of solitary large HCC remains a major treatment challenge. According to the current BCLC scheme, TACE is the recommended treatment for patients with intermediate stage HCC. TACE has been shown safe and effective in treating larger HCC.[13] However, therapeutic modalities including RFA or TACE are still potentially limited by a lack of complete tumor eradication.[4] Significant progress has been achieved in patient selection, surgical techniques, and post-operative management of HCC in recent years, and SR was associated with improved outcomes in carefully selected solitary large HCC patients.[5] To further clarify the impact of treatment selection on long-term prognosis, we analyzed a large cohort with solitary large HCC irrespective of their performance status, hepatic functional reserve or PVTT.
We demonstrate that for patients with solitary large HCC, SR was associated with a better overall survival compared with TACE.

Since patients undergoing SR are usually highly selected, we utilized propensity score matching analysis to minimize the confounding effect of treatment allocation in this non-randomized, retrospective study. In the propensity model, patients in the SR or TACE group were well matched in baseline characteristics, hepatic functional reserve and performance status. We found that the SR group had better prognosis than TACE group in the propensity model. Consistently, in the Cox multivariate model, TACE was confirmed a significant predictor associated with poor long-term survival compared with SR after adjusting for confounders in all-patient group and in patients selected in the propensity model. SR should be thus considered a priority treatment for patients with solitary large HCC.

Consistent with reports from other study groups, this study demonstrates the applicability of SR in patients with solitary large HCC irrespective of their performance status, liver reserve or presence of PVTT.[31] Moreover, we also suggest that patients with solitary large HCC should be classified at least as intermediate stage HCC, for which the recommended treatment would be TACE. These seemingly contradictory statements encourage clinicians to individualize HCC management to obtain better treatment results. The BCLC system has been acknowledged to stratify patients to distinct stages that subsequently link to specific therapies.[32] However, due to high heterogeneity among HCC patients especially at the intermediate stage, further sub-classification and refinement of the BCLC staging system is urgently needed.[33]

This study has a few limitations. First, the retrospective nature may make selection bias unavoidable even in the propensity score model. Although the baseline demographics were similar between treatment groups, there may be hidden characteristics that cannot be directly compared. Second, HCC is a highly heterogeneous cancer, and treatment allocation is partly dependent on physician’s preference. Third, certain co-morbid illnesses, including chronic heart or pulmonary diseases, were not included in the analysis. Last, the results of this study are from a single tertiary referral center, therefore external validation is needed from different sources.

In conclusion, our results suggest that patients with solitary large HCC should be classified at least as intermediate stage HCC. With improvement in patient selection and treatment strategy, solitary large HCC is not a contraindication to aggressive therapy. Further amendment to the BCLC scheme is urgently required. We confirm that SR offers better long-term survival than TACE in patients with solitary large HCC. Our data provide evidenced-based approach for cancer staging and treatment for this special patient group.

Author Contributions

Conceived and designed the experiments: PHL CWS TIH. Performed the experiments: Chi-YH Che-YH HCL. Analyzed the data: LPH YHH RCL. Contributed reagents/materials/analysis tools: Chi-YH YHL. Wrote the paper: TIH PHL Chi-YH.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 23/08/2015.

2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3):1020–2. doi: 10.1002/hep.24199 PMID: 21374666; PubMed Central PMCID: PMC3084991.

3. European Association For The Study Of The Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908–43. doi: 10.1016/j.jhep.2011.12.001 PMID: 22424438.
4. Tsoulfas G, Mekras A, Agorastou P, Kiskinis D. Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg. 2012; 82(7–8):510–7. doi: 10.1111/j.1445-2197.2012.06079.x PMID: 22548726.

5. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005; 140(5):450–7; discussion 7–8. doi: 10.1001/archsurg.140.5.450 PMID: 15897440.

6. Huo TI, Huang YW, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J Chin Med Assoc. 2005; 68(4):155–9. doi: 10.1016/S1726-4901(09)70239-4 PMID: 15850062.

7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329–38. doi: 10.1055/s-2007-1007122 PMID: 10518312.

8. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. Reply to Letter: “A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group”: When the Study Setting “Ignores” the Patients. Ann Surg. 2015; 262(1):e30–1. doi: 10.1097/SLA.0000000000000382 PMID: 24253157.

9. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. Reply to Letter: “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on 'Surgical Misinterpretation' of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity Within the BCLC? Ann Surg. 2015; 262(1):e18–9. doi: 10.1097/SLA.0000000000000336 PMID: 24263335.

10. Lin SM. Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer. 2013; 2(2):73–83. doi: 10.1159/000343843 PMID: 24159599; PubMed Central PMCID: PMCPMC3740711.

11. Cho YB, Lee KU, Lee HW, Cho EH, Yang SH, Cho JY, et al. Outcomes of hepatic resection for a single large hepatocellular carcinoma. World J Surg. 2007; 31(4):795–801. doi: 10.1007/s00268-006-0359-z PMID: 17345125.

12. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Surg Oncol. 2007; 14(10):2817–23. doi: 10.1245/s40434-007-9518-1 PMID: 17690940.

13. Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013; 24(11):1639–46. doi: 10.1016/j.jvir.2013.06.017 PMID: 23962438.

14. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013; 57(1):108–17. doi: 10.1002/hep.25950 PMID: 22806819.

15. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010; 53(1):108–17. doi: 10.1016/j.jhep.2010.01.038 PMID: 20451283.

16. Liu PH, Lee YH, Hsia CY, Huang YH, Chioo YY, et al. Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status. J Gastrointest Surg. 2014; 18(9):1623–31. doi: 10.1007/s11605-014-2546-9 PMID: 24871082.

17. Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, et al. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One. 2014; 9(2):e89373. doi: 10.1371/journal.pone.0089373 PMID: 24586728; PubMed Central PMCID: PMCPMC3933355.

18. Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, et al. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012; 152(5):809–20. doi: 10.1016/j.surg.2012.03.024 PMID: 22766361.

19. Huang YH, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, et al. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Aliment Pharmacol Ther. 2005; 21(6):687–94. doi: 10.1111/j.1365-2036.2005.02404.x PMID: 15771754.

20. Pearl J. Causality: models, reasoning, and inference. 2 ed. Cambridge UK: Cambridge University Press; 2009. 348–52 p.

21. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265–81. PMID: 9802183.

22. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011; 10(2):150–81. doi: 10.1002/pst.433 PMID: 20925139; PubMed Central PMCID: PMC3120982.
23. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013; 257(5):929–37. doi: 10.1097/SLA.0b013e31828329b8 PMID: 23426336.

24. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2):439–74. doi: 10.1007/s12072-010-9165-7 PMID: 20827404; PubMed Central PMCID: PMC2900561.

25. Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii41–8. PMID: 22997453.

26. Italian Association for the Study of the Liver, Panel AE, Committee AC, Bolondi L, Cillo U, Colombo M, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013; 45(8):712–23. doi: 10.1016/j.dld.2013.01.012 PMID: 23769756.

27. Mendez-Sanchez N, Ridruejo E, Alves de Mattos A, Chavez-Tapia NC, Zapata R, Parana R, et al. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol. 2014; 13 Suppl 1:S4–40. PMID: 24998696.

28. Bruix J, Fuster J. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. Ann Surg. 2015; 262(1):e30. doi:10.1097/SLA.0000000000000381 PMID: 24374519.

29. Mazzaferro V, Roayaie S, Poon R, Majno PE. Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg. 2015; 262(1):e17–8. doi:10.1097/SLA.0000000000000398 PMID: 24368644.

30. Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, et al. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology. 2015; 61(3):905–14. doi:10.1002/hep.27321 PMID: 25048515.

31. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009; 249(1):118–23. doi: 10.1097/SLA.0b013e3181904988 PMID: 19106686.

32. Livraghi T, Brambilla G, Carnaghi C, Tommasini MA, Torzilli G. Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol. 2010; 102(7):668–76. doi:10.1002/jso.21733 PMID: 20886553.

33. You T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146(7):1691–700 e3. doi: 10.1053/j.gastro.2014.02.032 PMID: 24583061.

34. Bruix J, Sherman M, Llovet JM, Beaugarand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421–30. PMID:11592607.

35. Bruix J, Sherman M, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002; 35(3):519–24. doi: 10.1053/jhep.2002.32089 PMID: 11870363.

36. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907–17. doi: 10.1016/S0140-6736(03)14964-1 PMID: 14667759.

37. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42(5):1208–36. doi: 10.1002/hep.20933 PMID: 16250051.

38. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1):61–74. doi: 10.1055/s-0030-1247133 PMID: 20179034.

39. Bolondi L, Burroughs A, dufour JF, Galli PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012; 32(4):348–59. doi: 10.1055/s-0032-1299006 PMID: 23397536.